Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pharming Group N-V stock

Own Pharming Group N-V stock in just a few minutes.

Pharming Group N.V. is an other business based in the US. Pharming Group N-V shares (PHAR) are listed on the NASDAQ and all prices are listed in US Dollars.

How to buy shares in Pharming Group N-V

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PHAR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Pharming Group N-V share price

Use our graph to track the performance of PHAR stocks over time.

Pharming Group N-V shares at a glance

Information last updated 2021-03-10.
52-week range$0.00 - $0.00
50-day moving average $0.00
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Pharming Group N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pharming Group N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pharming Group N-V financials

Gross profit TTM $0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin 0%
Book value N/A
Market capitalisation $0

TTM: trailing 12 months

Shorting Pharming Group N-V shares

There are currently 37,448 Pharming Group N-V shares held short by investors – that's known as Pharming Group N-V's "short interest". This figure is 229.9% up from 11,351 last month.

There are a few different ways that this level of interest in shorting Pharming Group N-V shares can be evaluated.

Pharming Group N-V's "short interest ratio" (SIR)

Pharming Group N-V's "short interest ratio" (SIR) is the quantity of Pharming Group N-V shares currently shorted divided by the average quantity of Pharming Group N-V shares traded daily (recently around inf billion). Pharming Group N-V's SIR currently stands at 0. In other words for every 100,000 Pharming Group N-V shares traded daily on the market, roughly 0 shares are currently held short.

To gain some more context, you can compare Pharming Group N-V's short interest ratio against those of similar companies.

However Pharming Group N-V's short interest can also be evaluated against the total number of Pharming Group N-V shares, or, against the total number of tradable Pharming Group N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pharming Group N-V's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Pharming Group N-V shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Pharming Group N-V shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Pharming Group N-V.

Find out more about how you can short Pharming Group N-V stock.

Pharming Group N-V share dividends

We're not expecting Pharming Group N-V to pay a dividend over the next 12 months.

Pharming Group N-V overview

Pharming Group N. V. , a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII) for the treatment of haemophilia A; and protein replacement treatments for enzyme-deficiency disorders, such as pompe and fabry diseases, as well as products for acute kidney injury. The company has partnerships with China State Institute of Pharmaceutical Industry and the Chengdu Institute of Biological Products for the development of new products; and development collaboration and license agreement with Novartis to develop and commercialize leniolisib (CDZ173), a small molecule phosphoinositide 3-kinase delta inhibitor to treat patients with activated phosphoinositide 3-kinase delta syndrome. Pharming Group N.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site